Publication at Third Faculty of Medicine |
2021
Abstract
Bronchogenic carcinoma is generally known for its poor sensitivity to treatment and rapid development of resistance. Nevertheless, survival is slowly increasing in patients with this diagnosis, thanks to modern drugs, including lorlatinib, a third-generation targeted therapy for patients with ALK or ROS1 rearrangements.
The detection rate of this genetic mutation is low, but it offers patients hope for therapeutic success and longer survival.